CME Presentations

Ovarian Cancer



  • Paul DiSilvestro, MD

    Paul DiSilvestro, MD

    Paul DiSilvestro, MD

    Professor, Obstetrics and Gynecology, Director, Division of Gynecologic Oncology

    Paul DiSilvestro, MD, is a Professor of Obstetrics and Gynecology and Director of the Division of Gynecologic Oncology at the Alpert School of Medicine at Brown University. Additionally, he is the Program Director in Women’s Oncology at Women and Infants Hospital (WIH) in Providence, Rhode Island. His research interests include clinical trials in gynecologic cancer, with special emphasis on national cooperative group clinical research. Dr. DiSilvestro is the Principal Investigator for NRG Oncology of the National Clinical Trials Network of the National Cancer Institute (NCI) Research at WIH. He is currently Co-Chair of the Gynecologic Cancer committee at NRG Oncology and a member of the Gynecologic Cancer Steering Committee of the NCI. Dr. DiSilvestro has served as a mentor throughout his career, with many of those mentorship experiences yielding published manuscripts and successful grant applications for the mentees.

CME Information

Global Logo PQH Logo
Navigating the Use of PARP Inhibitors to Treat Ovarian Cancer
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with The Chrysalis Initiative.


This activity is supported by educational grants from AstraZeneca Pharmaceuticals and Merck & Co., Inc.


This activity was released on November 8, 2022 and is valid until November 8, 2023. Requests for credit must be made no later than November 8, 2023.


The educational design of this activity addresses the needs of gynecologic oncologists, medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, pathologists, and other members of the multidisciplinary care team.


Ovarian cancer is the most common cause of gynecologic cancer-related death in women worldwide. Despite consistent developments with treatment strategies, management of advanced-stage disease remains a significant challenge. In addition, not all racial and ethnic groups have benefited equally, with various barriers impeding the timely and optimal care of many patients with ovarian cancer.

Join Dr. Paul DiSilvestro as he discusses the importance of biomarker testing, the rationale for using PARP inhibitors for the treatment of ovarian cancer, and updates to evidence-based guidelines. Dr. DiSilvestro will describe how to personalize the selection of maintenance therapy in the frontline and recurrent settings, outline strategies for appropriate monitoring and management of potential adverse events and provide approaches to reduce inequities in ovarian cancer care within different patient populations.


After completing this activity, the participant should be better able to:
  • Assess patient populations that would benefit from PARP therapy in frontline and recurrent maintenance settings.
  • Apply strategies for the timely recognition and management of adverse events.
  • Discuss patient‐provider approaches to improving equity in ovarian cancer care.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 45 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 100% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Paul DiSilvestro, MD
Director, Program in Women’s Oncology
Professor, Department of Obstetrics & Gynecology
Women & Infants Hospital
Warren Alpert Medical School, Brown University
Consulting Fee: AstraZeneca, GSK Tesaro

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Lauren Sinclair Nothing to disclose
Tariqa Ackbarali Nothing to disclose
Vandana Gupta Nothing to disclose
Alissa Yost Nothing to disclose
Frances Perez – Patient Participant Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at